Please be advised that Associates of Cape Cod, Inc. (ACC) has updated its Privacy Policy. By visiting our website or using services provided by ACC, you are accepting the processes and procedures described in the Privacy Policy.

ACC also uses cookies on our websites. Cookies allow us to give you the best browsing experience and help us to better understand how you use our site. You can disable cookies within your settings, but this may affect certain functionally on our website. Please read our updated Cookies Policy for information about the cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking "I Accept", you confirm that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of information by ACC in accordance with said policies.

About ACC | Careers | Contact | ACC Calendar | News & Notices | Educational Content | Catalogs | Home

Associates of Cape Cod, Inc.
ACC's Clinical Diagnostics

Clinical Diagnostics

ACC offers (1→3)-ß-D-glucan analysis to support the diagnosis of Invasive Fungal Disease (IFD) in at risk patients. Testing services are provided through our reference laboratory, Beacon Diagnostics®, a CLIA-certified laboratory specializing in (1→3)-ß-D-glucan analysis. Please visit the Beacon Diagnostics® Laboratory website for reference information, certificates/licenses and instructions on submitting samples.

In addition to our clinical diagnostics laboratory services we also offer the Fungitell® Kit which is an in-house diagnostic test for the detection of (1→3)-ß-D-glucan that clients can perform at their facility.

Patients at High Risk for IFD

Multiple studies have shown glucan to become elevated well in advance of conventional clinical signs and symptoms. The early diagnosis of fungal infection is associated with improved clinical outcome and is a value to clinicians. In contrast, delayed diagnosis and therapy of invasive fungal disease is associated with increased mortality. Hence, there is significant utility in the application of the Fungitell® test in at risk patients.

Immunosuppressed patients are at high risk for developing invasive fungal disease, which is often difficult to diagnose. Affected patient populations include:

© Copyright 2019 Associates of Cape Cod, Inc. 124 Bernard E. Saint Jean Dr., E. Falmouth, MA 02536, All Rights Reserved. Terms and Conditions
This website uses cookies to allow us to see how the site is used. The cookies cannot identify you. Click these links to learn more about our Privacy Policy and Cookies Policy.